CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Vedolizumab

Last Updated: February 20, 2015
Result type: Reports
Project Number: SR0421-000
Product Line: Reimbursement Review

Generic Name: Vedolizumab

Brand Name: Entyvio

Manufacturer: Takeda Canada Inc.

Therapeutic Area: Ulcerative colitis

Indications: Ulcerative Colitis

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: October 28, 2015

Recommendation Type: List with clinical criteria and/or conditions